

Research Article

Novel Irrigation Reduces Prosthetic Joint Infection Rates: Meta-analysis of 3 clinical studies

Vibhatsu Amin, M.D.^{1a}, Ravi Bashyal, M.D.^{1b}, Robert Harris, M.D.^{2c}, Al Parker^{3d}, Ronald Singer^{2e}

¹ Orthopedic Surgery, NorthShore University HealthSystem, ² Orthopedic Surgery, ³ Mathematical Sciences

Keywords: Prosthetic Joint Infection, Total Hip Arthroplasty, Total Knee Arthroplasty, Irrigation Solution, Xperience, Total Joint Arthroplasty

<https://doi.org/10.60118/001c.138887>

Journal of Orthopaedic Experience & Innovation

a Dr. Vibhatsu Amin is currently serving as an Adult Reconstruction Fellow at Endeavor Health NorthShore in Skokie, Illinois.

[Conflicts of Interest Statement for Dr. Vibhatsu Amin](#)

[Visit the Open Payments Data Page for Dr. Vibhatsu Amin](#)

b Ravi K. Bashyal, MD is a Chicago native and a orthopaedic surgeon specializing in minimally invasive hip and knee replacement surgery at Endeavor System in Chicago, IL where he is Vice-Chairman of Patient and Provider Experience, and Director of Outpatient Hip and Knee Replacement Surgery,. Dr. Bashyal trained as a resident in orthopaedic surgery at Washington University in St. Louis. He then completed a fellowship in adult hip and knee reconstruction at Harvard Medical School and Massachusetts General Hospital. He holds an academic appointment as Clinical Assistant Professor of Orthopaedic Surgery at the University of Chicago Pritzker School of Medicine. He also serves as the medical director and Chief Hip and Knee Replacement consultant for the National Basketball Association Retired Players Association. Dr. Bashyal currently maintains a busy clinical practice in Chicago performing approximately 600 minimally invasive total hip and knee replacements every year while also participating in clinical research and education.

[Visit Dr. Ravi Bashyal](#)

[Connect with Dr. Ravi Bashyal on LinkedIn](#)

[Conflicts of Interest Statement for Dr. Ravi Bashyal](#)

[Visit the Open Payments Data Page for Dr. Ravi Bashyal](#)

c Dr. Robert Harris is an orthopedic traumatologist with over 30 years of experience and currently serves as the Director of the Division of Orthopedics at Quillen College of Medicine, East Tennessee State University. He also leads as the Program Director of the Orthopedic Residency Program, where he has played a key role in shaping the next generation of orthopedic surgeons.

[Conflicts of Interest Statement for Dr. Robert Harris](#)

[Visit the Open Payments Data Page for Dr. Robert Harris](#)

d Dr. Al Parker has a Ph.d. in math, and completed post-docs at the University of California Santa Cruz in image analysis and at University of Otago in Bayesian statistics. He has been at the Center for Biofilm Engineering since 2008 where he is the lead biostatistician and in the Department of Mathematical Sciences as an Associate Research Professor at Montana State University. Dr. Parker is the consulting statistician to the Microbiological Branch Lab at US EPA, earning EPA's highest Scientific and Technology Achievement Award in 2015. He has worked extensively with standard setting organizations ASTM and AOAC to develop, assess and modify standard microbiological methods for regulatory purposes.

[Visit Al Parker, PhD](#)

[Connect with Al Parker, PhD on LinkedIn](#)

[Conflicts of Interest Statement for Al Parker, PhD](#)

e Dr. Ron Singer is an orthopedic surgeon who has devoted his career to refining minimally invasive surgical techniques as well as infection prevention and teaching these techniques to surgeons across the world, including India and Mexico. He currently practices general orthopedics, joint replacement and sports medicine at OrthoCarolina in Charlotte, NC—one of the largest, most comprehensive orthopedic practices in the nation. He is also the Founder and Chairman of the Board for The Surgery Center at Edgewater, recently recognized by Newsweek as one of America's Best Ambulatory Surgery Centers. Dr. Singer has served on the advisory boards of several organizations throughout his 30-year medical career, including Winston Hospitality, Avanos Medical, Nozin, TechMah Medical and Smith and Nephew. He has been named eight times as one of Charlotte's Top Docs by Charlotte Magazine and prides himself as a strong advocate for his patients.

[Visit Dr. Ronald Singer](#)

[Connect with Dr. Ronald Singer on LinkedIn](#)

[Conflicts of Interest Statement for Dr. Ronald Singer](#)

[Visit the Open Payments Data Page for Dr. Ronald Singer](#)

Prosthetic joint infection (PJI) in the setting of total joint arthroplasty represents significant morbidity and economic burden to patients and the healthcare system. We analyzed a non-toxic, no-rinse intraoperative antimicrobial irrigation solution (AIS) that was designed to combat infection. In this meta-analysis of three studies, the AIS rate of PJI was 0.727 per 1000 surgeries (95% CI: [0.041, 3.19]), which was significantly less than the standard of care (SOC) rate of infection of 4.854 per 1000 (95% CI: [1.178, 27.73]) ($p=0.045$). This corresponds to a reduction of 85% in the odds of PJI ($p = 0.045$, 95% CI: [24%, 99%]). When compared to the American Association of Hip and Knee Surgeons (AAHKS) estimate of 1 infection per 100 surgeries, the AIS rate of infection was significantly less ($p=0.004$). The use of this AIS intraoperatively represents an efficient and effective technique to combat PJI in the setting of total joint arthroplasty.

INTRODUCTION

For patient undergoing Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA) procedures, prosthetic joint infection (PJI) remains a daunting and formidable complication. PJI affects approximately 1-2% of patients undergoing elective joint replacements and represents a large financial burden, with estimated expenditures approaching \$1.85 billion by 2030 (Premkumar et al. 2021; American Association of Hip and Knee Surgeons, n.d.). Despite attempts to elucidate risk factors, mitigation techniques, and prophylactic methods to reduce PJI incidence, rates have remained unchanged for decades ("Proceedings of the Second International Consensus Meeting on Musculoskeletal Infection," n.d.; McMaster Arthroplasty Collective 2020).

Pre-operative and post-operative antibiotics remain a mainstay of infection prevention efforts in THA and TKA procedures. Several guidelines support the use of prophylactic pre-operative antibiotics (Berrios-Torres et al. 2017; Leaper and Edmiston 2017; Anderson et al. 2014; Parvizi, Gehrke, and Chen 2013). Post-operative intravenous antibiotics are oftentimes utilized, however, their efficacy in infection prevention is yet to be fully supported (Tan et al. 2019). Extended post-operative oral antibiotics have demonstrated reduction in short-term infection rates (Inabathula et al. 2018). Despite the efficacy of antibiotics, concerns remain regarding systemic toxicity and antibiotic stewardship.

Clinicians have begun employing various intraoperative irrigation solutions in an attempt to decrease PJI incidence. One such formation is Xperience (XP) (Next Science, LLC, Jacksonville, FL). XP is a nontoxic, no-rinse intraoperative antimicrobial irrigation solution (AIS) cleared for use by the United State Food and Drug Administration. It is comprised citric acid, sodium citrate, and sodium lauryl sulfate in water.

Previous *in vitro* testing has shown that XP is highly effective against planktonic bacteria and their biofilm superstructures that are responsible for PJI (Bashyal et al. 2022). Three recent retrospective clinical studies have investigated the use of XP in primary joint arthroplasty (Vatti et al. 2024; Singer 2024; Williams and Harris 2024). The aim of this meta-analysis is to pool the clinical studies together to evaluate the efficacy of this specific AIS on reducing PJI rates in the setting of primary hip and knee arthroplasty.

METHODS

The three studies included total hip and knee arthroplasty procedures performed by different orthopedic surgeons at each institution (Vatti et al. 2024; Singer 2024; Williams and Harris 2024). Intraoperative protocols varied, however, in each case, the solution was used to irrigate the surgical wound during various stages of the arthroplasty procedure and/or at the end. XP is comprised of 32.5 g/L citric acid, 31.3 g/L sodium citrate, and 1.00 g/L sodium lauryl sulfate in water. Given the lack of cytotoxicity of the solution, there was no secondary rinse required. Pre-operative and post-operative antibiotic protocols were not standardized across the three studies. Two of the studies lacked matched control groups, while the third study compared to historical data at their institution on PJI rates with the use of a povidone-iodine wash (Vatti et al. 2024). The primary outcome was 90-day PJI rate. The studies and treatment groups are summarized in Table 1. Given the lack of standardized control groups, 90-day PJI rates were compared to infection rates in a Standard of Care (SOC) group. Patients in the SOC group were treated with an intraoperative diluted (0.35%) topical povidone iodine soak for at least 3 minutes, followed up a pulsatile lavage rinse with normal saline.

To compare the AIS group with the SOC, a meta-analysis was applied to pool all three studies in Table 1. Further analysis was performed comparing the pooled AIS rate of PJI to a conservative national mean (Zeng et al. 2023; Ebrahimzadeh et al. 2023; Kobayashi et al. 2021). The meta-analysis was performed using a mixed effects logistic regression model with study as a random effect and group as a fixed effect (Papadimitropoulou et al. 2019). The two groups were compared using a 1-sided Wald test and 1-sided likelihood profile 95% CI of the odds ratio. Two-sided likelihood profile 95% CIs were generated for the rate of infection for each group. The statistical software R v4.4.1 package lme4 was used for all statistical calculations (R Core Team, n.d.; Bates et al. 2015).

RESULTS

Pooled across the 3 studies, a meta-analysis showed that the AIS rate of PJI was 0.727 per 1000 surgeries (95% CI: [0.041, 3.19]), which was statistically significantly less than the standard of care (SOC) rate of infection of 4.854 per 1000 (95% CI: [1.178, 27.73]) ($p=0.045$).

Table 1. Treatment Groups Across Studies and Corresponding PJI Incidence

Study	Treatment	Number of Surgeries	Number of PJI
Singer et al	AIS	524	1
Williams and Harris	AIS	381	0
Bashyal et al	AIS	471	0
Bashyal et al	SOC	824	4

This corresponds to a statistically significant reduction of 85% in the odds of PJI ($p = 0.045$, 95% CI: [24%, 99%]).

DISCUSSION

In this meta-analysis of total joint arthroplasties performed using a novel no-rinse irrigation solution, we found the PJI rate was significantly lower in the AIS group compared to a SOC group ($p=0.045$). This corresponded to an 85% reduction in the odds of PJI development ($p=0.045$). Despite the already relatively low PJI rate in the SOC group (0.48%), the use of this AIS still had enough efficacy as to result in a statistically significant reduction.

The number of elective total joint arthroplasties is only expected to rise in the coming years, with the annual THA and TKA numbers expected to be 652,000 and 1,272,000 in 2025, respectively²¹. It has been shown that the average cost for an infected THA and TKA is \$88,623 and \$116,383, respectively (Singh et al. 2019). Those values are substantially higher than the valued of non-infected THA and TKA counterparts, which are estimated to cost \$25,659 and \$28,249. Given the patient morbidity and economic burden PJI presents to the healthcare system, there is need to develop effective and novel practices for infection prevention.

The American Association of Hip and Knee Surgeons estimates the risk of prosthetic joint infection in hip and knee arthroplasty procedures at 1-2% (American Association of Hip and Knee Surgeons, n.d.). When compared to the lower threshold AAHKS estimate of 1 infection per 100 surgeries, the AIS rate of infection was significantly less ($p=0.004$). A more conservative estimate of national PJI rates is 0.5% (Zeng et al. 2023; Ebrahimzadeh et al. 2023; Kobayashi et al. 2021). When compared to this, the AIS rate of infection was still significantly decreased ($p=0.027$).

According to the National Institute of Health (NIH), a significant number of microbial infections are attributable to the formation of biofilm (Kapadia et al. 2016). Biofilm production is paramount to the development and pathogenesis of PJI ("NIH Guide: Research on Microbial Biofilms," n.d.). Any existing microbial presence can colonize intraoperative prosthesis and result in rapid formation of biofilm. Biofilm consist of bacteria as well as host parts that are created by fibrin, polymorphonuclear neutrophils, erythrocytes, fibroblasts, and other constituents (Khatoon et al. 2018). After maturing, biofilm can exhibit various defense mechanisms such as resistance to antibacterial treatments and host immune defenses (Buret et al. 1991).

This AIS was designed to cleanse and remove debris from surgical wounds, including microorganisms. Its design is based on patented technology aimed to prevent the formation of biofilm, as well as treat and remove matured biofilm. The irrigation solution incorporates a buffered pH modifier and surfactant, which work in combination to break down biofilm. The antimicrobial efficacy of the AIS was studied *in vitro* by Bashyal et al (Bashyal et al. 2022). After irrigating for 5 minutes, they showed high efficacy (at least a 6-log reduction) against planktonic bacteria (*Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli*, *Enterococcus faecalis*, *Enterobacter cloacae*). Furthermore, there was at least a 3-log reduction against yeast (*Candida albicans*, *Candida tropicalis*). This *in vitro* study also showed efficacy against biofilm bacteria, with at least a 2-log reduction of *S. epidermidis*, *Pseudomonas* and *Cutibacterium acnes* after 1 hour of irrigation, and a 4-log reduction of *S. aureus* after 30 minutes of irrigation. This study also showed persistent inhibition of biofilm regrowth from 5 minutes to 5 hours after AIS exposure. As highlighted previously, this AIS is a no-rinse solution. A contributing factor to the lower infection rate in the experimental group may stem from its long-lasting presence, even after wound closure.

There are several limitations to this analysis. First, surgical techniques were not standardized across the three retrospective studies and thus the AIS was used at different times throughout the procedure. Although this represents variation in surgical protocol, it shows that the use of the AIS at any point during the procedure can be beneficial. Second, two of the studies did not have control groups. To combat this, we compared PJI rates in the pooled AIS group to the PJI rate of the SOC from one of the included studies, which was 0.48%. This SOC PJI rate is similar to conservative national estimates (Zeng et al. 2023; Ebrahimzadeh et al. 2023; Kobayashi et al. 2021).

In conclusion, in a pooled meta-analysis of three studies using the AIS irrigation solution, we found that the use of this AIS was associated with a significantly lower PJI rate as compared to a SOC group. Compared to the AAHKS estimate and even more conservative national means, the AIS treatment group had decreased rates of PJI. As efforts are continuously made to prevent PJI and optimize total joint arthroplasty, the use of this AIS represents a meaningful development in infection prevention strategy.

Submitted: February 07, 2025 EDT. Accepted: May 30, 2025 EDT. Published: September 02, 2025 EDT.



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-ND-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc-nd/4.0> and legal code at <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> for more information.

REFERENCES

- American Association of Hip and Knee Surgeons. n.d. "Infection and Your Joint Replacement." Accessed January 26, 2025. <https://hipkneeinfo.org/general/infection-and-your-joint-replacement/>.
- Anderson, D. J., K. Podgorny, S. I. Berríos-Torres, D. W. Bratzler, E. P. Dellinger, L. Greene, et al. 2014. "Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update." *Infect Control Hosp Epidemiol* 35 (6): 605–27. <https://doi.org/10.1086/676022>.
- Bashyal, R., M. Mathew, E. Bowen, G. James, and D. Stulberg. 2022. "A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty." *Journal of Arthroplasty* 37 (7): 647–52. <https://doi.org/10.1016/j.arth.2022.01.045>.
- Bates, Douglas, Martin Maechler, Ben Bolker, and Steve Walker. 2015. "Fitting Linear Mixed Effects Models Using Lme4." *Journal of Statistical Software* 67 (1): 1–48. <https://doi.org/10.18637/jss.v067.i01>.
- Berríos-Torres, S. I., C. A. Umscheid, D. W. Bratzler, B. Leas, E. C. Stone, R. R. Kelz, et al. 2017. "Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection." *JAMA Surgery* 152 (8): 784–91. <https://doi.org/10.1001/jamasurg.2017.0904>.
- Buret, A., K. H. Ward, M. E. Olson, and J. W. Costerton. 1991. "An in Vivo Model to Study the Pathobiology of Infectious Biofilms on Biomaterial Surfaces." *J Biomed Mater Res* 25 (7): 865–74. <https://doi.org/10.1002/jbm.820250706>.
- Ebrahimzadeh, M. H., M. R. Safdari, A. Moradi, S. Rastaghi, and M. Daliri. 2023. "How Effective Is Diluted Povidone-Iodine in Preventing Periprosthetic Joint Infection in Total Joint Arthroplasty (TJA)? An Updated Systematic Review and Meta-Analysis." *BMC Musculoskelet Discord* 24 (1): 416. <https://doi.org/10.1186/s12891-023-06548-x>.
- Inabathula, A., J. E. Dilley, M. Ziemba-Davis, L. C. Warth, K. A. Azzam, P. H. Ireland, et al. 2018. "Extended Oral Antibiotic Prophylaxis in High-Risk Patients Substantially Reduces Primary Total Hip and Knee Arthroplasty 90-Day Infection Rate." *J Bone Joint Surg Am* 100 (24): 2103–9. <https://doi.org/10.2106/JBJS.17.01485>.
- Kapadia, B. H., S. Banerjee, J. J. Cherian, K. J. Bozic, and M. A. Mont. 2016. "The Economic Impact of Periprosthetic Infections After Total Hip Arthroplasty at a Specialized Tertiary-Care Center." *J Arthroplasty* 31 (7): 1422–26. <https://doi.org/10.1016/j.arth.2016.01.021>.
- Khatoon, Z., C. D. McTiernan, E. J. Suuronen, T. F. Mah, and E. I. Alarcon. 2018. "Bacterial Biofilm Formation on Implantable Devices and Approaches to Its Treatment and Prevention." *Heliyon* 4 (12): e01067. <https://doi.org/10.1016/j.heliyon.2018.e01067>.
- Kobayashi, N., E. Kamono, K. Maeda, T. Misumi, Y. Yukizawa, and Y. Inaba. 2021. "Effectiveness of Diluted Povidone-Iodine Lavage for Preventing Periprosthetic Joint Infection: An Updated Systematic Review and Meta-Analysis." *J Orthop Surg Res* 16 (1): 569. <https://doi.org/10.1186/s13018-021-02703-z>.
- Leaper, D. J., and C. E. Edmiston. 2017. "World Health Organization: Global Guidelines for the Prevention of Surgical Site Infection." *J Hosp Infect* 95 (2): 135–36. <https://doi.org/10.1016/j.jhin.2016.12.016>.
- McMaster Arthroplasty Collective. 2020. "Risk Factors for Periprosthetic Joint Infection Following Primary Total Hip Arthroplasty: A 15-Year, Population-Based Cohort Study." *J Bone Joint Surg Am* 102 (6): 503–9. <https://doi.org/10.2106/JBJS.19.00537>.
- "NIH Guide: Research on Microbial Biofilms." n.d. Accessed November 8, 2024. <https://grants.nih.gov/grants/guide/pa-files/pa-03-047.html>.
- Papadimitropoulou, Katerina, Theo Stijnen, Olaf M. Dekkers, and Saskia le Cessie. 2019. "One-Stage Random Effects Meta-Analysis Using Linear Mixed Models for Aggregate Continuous Outcome Data." *Research Synthesis Methods* 10 (3): 360–75. <https://doi.org/10.1002/jrsm.1331>.
- Parvizi, J., T. Gehrke, and A.F. Chen. 2013. "Proceedings of the International Consensus on Periprosthetic Joint Infection." *The Bone & Joint Journal* 95-B (11): 1450–52. <https://doi.org/10.1302/0301-620X.95B11.33135>.
- Premkumar, A., D. A. Kolin, K. X. Farley, J. M. Wilson, A. S. McLawhorn, M. B. Cross, et al. 2021. "Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States." *J Arthroplasty* 36 (5): 1484–89. <https://doi.org/10.1016/j.arth.2020.12.005>.
- "Proceedings of the Second International Consensus Meeting on Musculoskeletal Infection." n.d. Accessed November 3, 2024. <https://icmphilly.com/document/>.
- R Core Team. n.d. *A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing. Accessed September 2, 2024. <https://www.R-project.org/>.
- Singer, R. W. 2024. "Real-World Evidence of the Impact of a Novel Surgical Irrigant on Surgical Site Infections in Primary Total Knee Arthroplasty Performed at an Ambulatory Surgery Center." *Surgical Infections* 25 (3). <https://doi.org/10.1089/sur.2023.304>.
- Singh, J. A., S. Yu, L. Chen, and J. D. Cleveland. 2019. "Rates of Total Joint Replacement in the United States: Future Projections to 2020–2040 Using the National Inpatient Sample." *J Rheumatol* 46 (9): 1134–40. <https://doi.org/10.3899/jrheum.170990>.
- Tan, T. L., N. Shohat, A. J. Rondon, C. Foltz, K. Goswami, S. P. Ryan, et al. 2019. "Perioperative Antibiotic Prophylaxis in Total Joint Arthroplasty: A Single Dose Is as Effective as Multiple Doses." *J Bone Joint Surg Am* 101 (5): 429–37. <https://doi.org/10.2106/JBJS.18.00336>.

- Vatti, L., R. Gonipath, C. Heshmat, S. Lariosa, S. Rabbitt, and R. Bashyal. 2024. "The Use of a Novel Surgical Irrigant May Be Associated with Decreased Incidence of Surgical Site Infections." *Journal of Orthopaedic Experience & Innovation* 5 (2). <https://doi.org/10.60118/001c.121295>.
- Williams, M., and R. M. Harris. 2024. "Efficacy of a Novel Intraoperative Surgical Irrigant in Preventing Periprosthetic Joint Infections in Primary Knee, Hip, and Shoulder Arthroplasties: A Retrospective Analysis." *Orthopedic Surgery* 16 (6): 1277–83. <https://doi.org/10.1111/os.14052>.
- Zeng, Z. J., F. M. Yao, W. He, Q. S. Wei, and M. C. He. 2023. "Incidence of Periprosthetic Joint Infection after Primary Total Hip Arthroplasty Is Underestimated: A Synthesis of Meta-Analysis and Bibliometric Analysis." *J Orthop Surg Res* 18 (1): 610. <https://doi.org/10.1186/s13018-023-04060-5>.